Cargando…
Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET
BACKGROUND: Activated hepatic stellate cells (HSCs), which express integrin αvβ3, are a major fibrogenic factor in NASH pathophysiology. (18)F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ((18)F-FPP-RGD(2)) has been used as a PET probe for tumors expressing integrin αvβ3. The aim of t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981157/ https://www.ncbi.nlm.nih.gov/pubmed/29855729 http://dx.doi.org/10.1186/s13550-018-0394-4 |
_version_ | 1783327987737821184 |
---|---|
author | Rokugawa, Takemi Konishi, Haruyo Ito, Miwa Iimori, Hitoshi Nagai, Ryohei Shimosegawa, Eku Hatazawa, Jun Abe, Kohji |
author_facet | Rokugawa, Takemi Konishi, Haruyo Ito, Miwa Iimori, Hitoshi Nagai, Ryohei Shimosegawa, Eku Hatazawa, Jun Abe, Kohji |
author_sort | Rokugawa, Takemi |
collection | PubMed |
description | BACKGROUND: Activated hepatic stellate cells (HSCs), which express integrin αvβ3, are a major fibrogenic factor in NASH pathophysiology. (18)F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ((18)F-FPP-RGD(2)) has been used as a PET probe for tumors expressing integrin αvβ3. The aim of this study was to assess the potential of PET with (18)F-FPP-RGD(2) to detect hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mice. RESULTS: Thirty-two male C57BL/6 mice aged 6 weeks were fed a choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD) for 3 and 8 weeks. (18)F-FPP-RGD(2) PET imaging of the liver was performed at 3 and 8 weeks after CDAHFD feeding. After PET scanning, levels of hepatic integrin αvβ, 3α-smooth muscle actin (α-SMA), and collagen type 1 alpha 1(col1a1) were measured. Histopathological analysis of hepatic steatosis, inflammation, and fibrosis, as well as blood biochemistry analysis, was also performed. CDAHFD for 3 and 8 weeks produced a moderate-to-severe steatosis and inflammation of the liver in mice. NAFLD activity score (NAS) in mice fed the CDAHFD for 3 and 8 weeks were more than 4 indicating NASH or borderline NASH pathology. Fibrosis was observed only in mice fed the CDAHFD for 8 weeks. PET imaging showed that the hepatic standardized uptake value, SUV(80–90 min), was increased with prolonged CDAHFD feeding compared with the respective controls (CDAHFD 3 weeks 0.32 ± 0.06 vs 0.48 ± 0.05, p < 0.01; CDAHFD 8 weeks 0.35 ± 0.04 vs 0.75 ± 0.07, p < 0.01, respectively). Prolonged CDAHFD feeding increased hepatic mRNA and protein levels of integrin αv and β3 at 3 and 8 weeks. Hepatic (18)F-FPP-RGD(2) uptake and amount of integrin αv and β3 protein were well correlated (r = 0.593, p < 0.05 and r = 0.835, p < 0.001, respectively). Hepatic (18)F-FPP-RGD(2) uptake also showed a positive correlation with Sirius red-positive area. CONCLUSIONS: The hepatic uptake of (18)F-FPP-RGD(2) correlated well with integrin αv and β3 expression and histological fibrosis in a mouse model of NASH, suggesting the predictability of fibrosis in NASH pathology. |
format | Online Article Text |
id | pubmed-5981157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-59811572018-06-14 Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET Rokugawa, Takemi Konishi, Haruyo Ito, Miwa Iimori, Hitoshi Nagai, Ryohei Shimosegawa, Eku Hatazawa, Jun Abe, Kohji EJNMMI Res Original Research BACKGROUND: Activated hepatic stellate cells (HSCs), which express integrin αvβ3, are a major fibrogenic factor in NASH pathophysiology. (18)F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ((18)F-FPP-RGD(2)) has been used as a PET probe for tumors expressing integrin αvβ3. The aim of this study was to assess the potential of PET with (18)F-FPP-RGD(2) to detect hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mice. RESULTS: Thirty-two male C57BL/6 mice aged 6 weeks were fed a choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD) for 3 and 8 weeks. (18)F-FPP-RGD(2) PET imaging of the liver was performed at 3 and 8 weeks after CDAHFD feeding. After PET scanning, levels of hepatic integrin αvβ, 3α-smooth muscle actin (α-SMA), and collagen type 1 alpha 1(col1a1) were measured. Histopathological analysis of hepatic steatosis, inflammation, and fibrosis, as well as blood biochemistry analysis, was also performed. CDAHFD for 3 and 8 weeks produced a moderate-to-severe steatosis and inflammation of the liver in mice. NAFLD activity score (NAS) in mice fed the CDAHFD for 3 and 8 weeks were more than 4 indicating NASH or borderline NASH pathology. Fibrosis was observed only in mice fed the CDAHFD for 8 weeks. PET imaging showed that the hepatic standardized uptake value, SUV(80–90 min), was increased with prolonged CDAHFD feeding compared with the respective controls (CDAHFD 3 weeks 0.32 ± 0.06 vs 0.48 ± 0.05, p < 0.01; CDAHFD 8 weeks 0.35 ± 0.04 vs 0.75 ± 0.07, p < 0.01, respectively). Prolonged CDAHFD feeding increased hepatic mRNA and protein levels of integrin αv and β3 at 3 and 8 weeks. Hepatic (18)F-FPP-RGD(2) uptake and amount of integrin αv and β3 protein were well correlated (r = 0.593, p < 0.05 and r = 0.835, p < 0.001, respectively). Hepatic (18)F-FPP-RGD(2) uptake also showed a positive correlation with Sirius red-positive area. CONCLUSIONS: The hepatic uptake of (18)F-FPP-RGD(2) correlated well with integrin αv and β3 expression and histological fibrosis in a mouse model of NASH, suggesting the predictability of fibrosis in NASH pathology. Springer Berlin Heidelberg 2018-05-31 /pmc/articles/PMC5981157/ /pubmed/29855729 http://dx.doi.org/10.1186/s13550-018-0394-4 Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Rokugawa, Takemi Konishi, Haruyo Ito, Miwa Iimori, Hitoshi Nagai, Ryohei Shimosegawa, Eku Hatazawa, Jun Abe, Kohji Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET |
title | Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET |
title_full | Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET |
title_fullStr | Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET |
title_full_unstemmed | Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET |
title_short | Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET |
title_sort | evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (nash) model mouse by (18)f-fpp-rgd(2) pet |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981157/ https://www.ncbi.nlm.nih.gov/pubmed/29855729 http://dx.doi.org/10.1186/s13550-018-0394-4 |
work_keys_str_mv | AT rokugawatakemi evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet AT konishiharuyo evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet AT itomiwa evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet AT iimorihitoshi evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet AT nagairyohei evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet AT shimosegawaeku evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet AT hatazawajun evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet AT abekohji evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet |